Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Ramalho Carvalho, João ^a   Pires, Malini ^a   Lisboa, Susana ^a   Graça, Inês ^a   Rocha, Patrícia ^a   Barros Silva, João Diogo ^a   Savva Bordalo, Joana ^a   Maurício, Joaquina ^a   Resende, Mário ^c   Teixeira, Manuel R ^a,b   Honavar, Mrinalini ^c   Henrique, Rui ^a,b   Jerónimo, Carmen ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL PEDRO HISPANO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 10; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENE ACTIVITY; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE PROBE; GENE SILENCING; GENETIC ANALYSIS; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MGMT GENE; MONOSOMY; ONCOGENE; PREDICTIVE VALUE; PROGNOSIS; PROMOTER REGION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84874862608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058206     Document Type: Article

References (37)

1. Pegg AE, Dolan ME, Moschel RC, (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223.
2. Pegg AE, (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129.
3. Gerson SL, (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307.
4. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
5. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, et al. (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22: 8835-8844.
6. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, et al. (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11: 348-356.
7. Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, et al. (1999) A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog 24: 90-98.
8. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG, (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797.
9. Qian XC, Brent TP, (1997) Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57: 3672-3677.
10. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, et al. (2002) Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94: 26-32.
11. Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M,et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22: 301-309.
12. Xue HC, Wang JM, Xu B, Guo GP, Hua ZL, et al. (2008) [Correlation of aberrant methylation of MGMT gene to MTHFR C677T genetic polymorphisms in esophageal squamous cell carcinoma]. Ai Zheng 27: 1256-1262.
13. Smith-Sorensen B, Lind GE, Skotheim RI, Fossa SD, Fodstad O, et al. (2002) Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene 21: 8878-8884.
14. Choy KW, Lee TC, Cheung KF, Fan DS, Lo KW, et al. (2005) Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma. Neoplasia 7: 200-206.
15. Wen PY, Kesari S, (2008) Malignant gliomas in adults. N Engl J Med 359: 492-507.
16. Jansen M, Yip S, Louis DN Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9: 717-726.
17. Bourne TD, Schiff D Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6: 695-701.
18. Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP,et al. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121: 651-661.
19. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G,et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97: 311-322.
20. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710.
21. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, et al. (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65: 1678-1686.
22. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, et al. (2002) Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 62: 6205-6210.
23. Wemmert S, Ketter R, Rahnenfuhrer J, Beerenwinkel N, Strowitzki M, et al. (2005) Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 7: 883-893.
24. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
25. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, et al. (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065.
26. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, et al. (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33: e128.
27. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, et al. (2009) MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27: 5881-5886.
28. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M,et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res 16: 5842-5851.
29. van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE,et al. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 103: 29-35.
30. Barros-Silva JD, Ribeiro FR, Rodrigues A, Cruz R, Martins AT,et al. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer. Genes Chromosomes Cancer 50: 662-671.
31. von Deimling A, Korshunov A, Hartmann C The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21: 74-87.
32. Preusser M, (2009) MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 24: 511-518.
33. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, et al. (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101: 124-131.
34. Christians A, Hartmann C, Benner A, Meyer J, von Deimling A,et al. Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. PLoS One 7: e33449.
35. Havik AB, Brandal P, Honne H, Dahlback HS, Scheie D,et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med 10: 36.
36. Hata N, Yoshimoto K, Yokoyama N, Mizoguchi M, Shono T, et al. (2006) Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis. Clin Chem 52: 370-378.
37. Robinson MD, Stirzaker C, Statham AL, Coolen MW, Song JZ,et al. Evaluation of affinity-based genome-wide DNA methylation data: effects of CpG density, amplification bias, and copy number variation. Genome Res 20: 1719-1729.